Researchers from Harvard Medical School, Boston, have found that most individuals with acute myeloid leukemia (AML) inappropriately express a protein known as CDX2 in their leukemic cells. CDX2 regulates the expression of a number of genes that encode members of the HOX family of proteins, which might provide a new set of targets for the treatment of individuals with AML.>>> Discuss This Story
